Pfizer Stock News

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

This week, 175 companies in the S&P 500 index report quarterly results, making it the busiest for the U.S. earnings reporting season overall. But amid the stampede, much of Wall Street's attention wil

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored) If you want your portfolio to pay you cash like clockwork, it's time to stop blindly following conventional wisdom li

Pfizer has better prospects than meet the eye. Brookfield Infrastructure's asset rotation strategy should drive growth and higher distributions.

AbbVie is an unstoppable passive income machine. Eli Lilly offers a sizzling stock performance and a growing dividend.

Dividend stocks can be a great way to build wealth. If you are a long-term investor and believe in dividend reinvesting, you could generate above-average returns over a few years.

Pfizer (NYSE: PFE) is scheduled to report its Q1 2024 results on Wednesday, May 1. We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis.

Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e

The treatment, Beqvez, will be available by prescription to eligible patients this quarter.

Pfizer, Bank of Nova Scotia, and AT&T all offer high yields of at least 6.5%. These stocks not only offer high payouts, they also have long-term potential.

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.

Markets were scared to wake up to the Federal Reserve (the Fed) pulling the rug. After pricing in the proposed interest rate cuts for 2024, which were set to be implemented by March, then May, and now

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-1

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline

A financial advisor can help you understand the advantages and disadvantages of investment properties.